Distribution of pathogens and antimicrobial resistance in bacteraemia according to hospitalization duration: a nationwide surveillance study in Switzerland.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 17 12 2020
revised: 08 04 2021
accepted: 21 04 2021
pubmed: 3 5 2021
medline: 13 1 2022
entrez: 2 5 2021
Statut: ppublish

Résumé

Changing microorganism distributions and decreasing antibiotic susceptibility with increasing length of hospital stay have been demonstrated for the colonization or infection of selected organ systems. We wanted to describe microorganism distribution or antibiotic resistance in bacteraemia according to duration of the hospitalization using a large national epidemiological/microbiological database (ANRESIS) in Switzerland. We conducted a nationwide, observational study on bacteraemia using ANRESIS data from 1 January 2008 to 31 December 2017. We analysed data on bacteraemia from those Swiss hospitals that sent information on a regular basis during the entire study period. We described the pathogen distribution and specific trends of resistance during hospitalization for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Serratia marcescens and Staphylococcus aureus. We included 28 318 bacteraemia isolates from 90 Swiss hospitals. The most common aetiology was E. coli (33.4%, 9459), followed by S. aureus (16.7%, 4721), K. pneumoniae (7.1%, 2005), Enterococcus faecalis (5.2%, 1473), P. aeruginosa (4.3%, 1228), Streptococcus pneumoniae (4.3%, 1208) and Enterococcus faecium (3.9%, 1101). We observed 489 (1.73%) S. marcescens isolates. We observed an increasing trend for E. faecium (from 1.5% at day 0 to 13.7% at day 30; p < 0.001), K. pneumoniae (from 6.1% to 7.8%, p < 0.001) and P. aeruginosa (from 2.9% to 13.7%, p < 0.001) with increasing duration of hospitalization; and decreasing trends for E. coli (from 41.6% to 21.6%; p < 0.001) and S. aureus (p < 0.001). Ceftriaxone resistance among E. coli remained stable for the first 15 days of hospitalization and then increased. Ceftriaxone resistance among K. pneumoniae and S. marcescens and oxacillin resistance among S. aureus increased linearly during the hospitalization. Cefepime resistance among P. aeruginosa remained stable during the hospitalization. We showed that hospitalization duration is associated with a species- and antibiotic class-dependent pattern of antimicrobial resistance.

Identifiants

pubmed: 33933567
pii: S1198-743X(21)00212-3
doi: 10.1016/j.cmi.2021.04.025
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Ceftriaxone 75J73V1629

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1820-1825

Investigateurs

A Burnens (A)
A Cherkaoui (A)
C Corradi (C)
O Dubuis (O)
A G Viollier (AG)
A Egli (A)
V Gaia (V)
D Koch (D)
A Kronenberg (A)
S L Leib (SL)
J Marschall (J)
P Nordmann (P)
V Perreten (V)
J-C Piffaretti (JC)
G Prod'hom (G)
J Schrenzel (J)
A F Widmer (AF)
G Zanetti (G)
R Zbinden (R)

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Niccolò Buetti (N)

Infection Control Programme, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland; Department of Infectious Diseases, Bern University Hospital and University of Bern, Switzerland; UMR 1137-IAME Team 5-DeSCID: Decision Sciences in Infectious Diseases, Control and Care Inserm, University Paris Diderot, Sorbonne Paris Cité, Paris, France. Electronic address: niccolo.buetti@gmail.com.

Jonas Marschall (J)

Department of Infectious Diseases, Bern University Hospital and University of Bern, Switzerland.

Jean-François Timsit (JF)

UMR 1137-IAME Team 5-DeSCID: Decision Sciences in Infectious Diseases, Control and Care Inserm, University Paris Diderot, Sorbonne Paris Cité, Paris, France.

Andrew Atkinson (A)

Department of Infectious Diseases, Bern University Hospital and University of Bern, Switzerland.

Andreas Kronenberg (A)

Institute for Infectious Diseases, University of Bern, Bern, Switzerland.

Rami Sommerstein (R)

Department of Infectious Diseases, Bern University Hospital and University of Bern, Switzerland; Infectious Diseases and Hospital Epidemiology, Hirslanden Central Switzerland, Lucerne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH